Printer Friendly

RIBI IMMUNOCHEM ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

 HAMILTON, Mont., Jan. 26 /PRNewswire/ -- Ribi ImmunoChem Research Inc. (NASDAQ: RIBI) today announced that it has filed an S-3 Registration Statement with the Securities and Exchange Commission to offer 3,000,000 shares of common stock (plus an additional 450,000 shares to cover over-allotments, if any). All the shares will be sold by the company. The offering is being underwritten by Hambrecht & Quist Inc.
 Ribi ImmunoChem Research Inc. is developing products that stimulate the immune system to generate a cascade of natural agents to treat and prevent human disease. Ribi immunostimulants are designed to be combined with disease-specific antigens to direct the immune system to respond to a particular cancer or infectious disease or to be used to produce a generalized immune response to prevent conditions such as septic shock and post-ischemic reperfusion injury.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any such state or jurisdiction.
 Copies of the preliminary prospectus relating to the offering may be obtained from Hambrecht & Quist Inc., One Bush St., 18th Floor, San Francisco, CA 94104, 415-576-3423.
 -0- 1/26/93
 /CONTACT: Jeffrey S. McDowell, corporate information manager, of Ribi ImmunoChem Research, 406-363-6214, ext. 153/
 (RIBI)


CO: Ribi ImmunoChem Research Inc. ST: Montana IN: MTC SU: OFR

SW-LM -- SE016 -- 9226 01/26/93 15:51 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 26, 1993
Words:300
Previous Article:KEYSTONE HERITAGE GROUP, INC. REPORTS EARNINGS, DECLARES REGULAR QUARTERLY CASH DIVIDEND
Next Article:AMERICAN ELECTRIC POWER COMPANY DECLARES REGULAR DIVIDEND
Topics:


Related Articles
RIBI IMMUNOCHEM CLOSES $11 MILLION PRIVATE PLACEMENT WITH HAMBRECHT & QUIST, D. BLECH & CO.
RIBI IMMUNOCHEM TO EXPAND FACILITY FOR MELACINE PRODUCTION; FACILITY TO EXPAND MELACINE MANUFACTURING CAPACITY 50-FOLD
RIBI IMMUNOCHEM WITHDRAWS PUBLIC OFFERING
RIBI IMMUNOCHEM REPORTS FIRST-QUARTER FINANCIAL RESULTS
RIBI IMMUNOCHEM AND LIDAK PHARMACEUTICALS TO COLLABORATE ON POTENTIAL SECOND-GENERATION THERACCINE TECHNOLOGY
RIBI, AMERICAN CYANAMID COMPLETE CO-EXCLUSIVE ADJUVANT LICENSE/SUPPLY AGREEMENTS
MARK I. GREENE, M.D., PH.D., ELECTED TO RIBI IMMUNOCHEM BOARD OF DIRECTORS
RIBI IMMUNOCHEM RECEIVES PACE AWARD FROM UNITED STATES DEPARTMENT OF COMMERCE OFFICE OF TECHNOLOGY POLICY
RIBI COMPLETES ADJUVANT LICENSE AGREEMENT FOR NEW SMITHKLINE BEECHAM CANCER VACCINES IN DEVELOPMENT
Ribi ImmunoChem's MPL Adjuvant System Critical to Efficacy of Malaria Vaccine in Human Challenge Study

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters